secwatch / observer
8-K filed May 18, 2023, 7:59 PM ET ticker EBS CIK 0001367644
debt confidence high sentiment neutral materiality 0.65

Emergent BioSolutions Inc. (EBS): debt financing — Emergent BioSolutions amends credit facility, extends maturity to 2025, reduces revolver to $300M

Emergent BioSolutions Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Emergent BioSolutions Inc. amended credit facility with Wells Fargo Bank, National Association, as administrative agent at SOFR plus a margin of 6.00% until March 31, 2024 maturing May 15, 2025.

Instrument
credit facility
Counterparty
Wells Fargo Bank, National Association, as administrative agent
Rate
SOFR plus a margin of 6.00% until March 31, 2024
Maturity
May 15, 2025
Event
amendment
Exact text from the filing
The Credit Agreement Amendment amends the Existing Credit Agreement to, among other things, (a) extend the maturity date of the Senior Secured Credit Facilities from October 13, 2023 to May 15, 2025, (b) reduce the available commitments under the Revolving Credit Facility from $600.0 million to $300.0 million
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Emergent BioSolutions Inc. amended Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement with Wells Fargo Bank, National Association, as administrative agent, and certain lenders (effective 2023-05-15).

Action
amendment
Agreement
credit facility
Counterparty
Wells Fargo Bank, National Association, as administrative agent, and certain lenders
Effective
2023-05-15
Exact text from the filing
On May 15, 2023, Emergent BioSolutions Inc. (the “Company”) entered into that certain Fourth Amendment to Amended and Restated Credit Agreement, Waiver and First Amendment to Amended and Restated Collateral Agreement (the “Credit Agreement Amendment”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”) and certain lenders party thereto.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Emergent BioSolutions Inc. entered into Equity Distribution Agreement with Evercore Group L.L.C. and RBC Capital Markets, LLC valued at $150,000,000 (effective 2023-05-17).

Action
entry
Agreement
atm program
Counterparty
Evercore Group L.L.C. and RBC Capital Markets, LLC
Value
$150,000,000
Effective
2023-05-17
Exact text from the filing
On May 17, 2023, the Company entered into an Equity Distribution Agreement (the “Distribution Agreement”) with Evercore Group L.L.C. and RBC Capital Markets, LLC (together, the “Managers”), as sales agents, under which the Company may offer and sell its common stock, par value $0.001 per share, from time to time having an aggregate offering price of up to $150,000,000 (the “Shares”) during the term of the Distribution Agreement through the Managers.
View on SEC.gov

Browse all debt financings →

Emergent BioSolutions Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-147301
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.